Refine
Year of publication
Document Type
- Doctoral Thesis (37)
- Article (28)
Has Fulltext
- yes (65)
Is part of the Bibliography
- no (65)
Keywords
- - (15)
- Vorhofflimmern (4)
- Diabetes mellitus (3)
- Proteomanalyse (3)
- B-Zelle (2)
- Biomaterial (2)
- CRMP2 (2)
- Cytokine (2)
- Insulin (2)
- Langerhans-Inseln (2)
- MICAL (2)
- Mas receptor (2)
- Mas-Rezeptor (2)
- PSMC5 (2)
- Prostatakrebs (2)
- Proteine (2)
- Renin-Angiotensin-System (2)
- TPD52 (2)
- Thioredoxine (2)
- Titan (2)
- atrial fibrillation (2)
- autoinflammation (2)
- proteasome (2)
- proteasomopathy (2)
- redox signaling (2)
- thermodynamics (2)
- 1-MT (1)
- ACE2 (1)
- APP (1)
- Abdominal fat (1)
- Acrylsäure (1)
- Acute decompensated heart failure (1)
- Allylamin (1)
- Alzheimer's disease (1)
- AminopeptidaseN (1)
- Androgen-Rezeptor (1)
- Androgenrezeptor (1)
- Angiogenese (1)
- Angiotensin-(1-7) (1)
- Antibacterial host defense (1)
- Apoptoserate (1)
- Atrial Fibrillation (1)
- Autoantikörper (1)
- BETA2 (1)
- BRIN-BD11-Insulinomazellen (1)
- Beschichtung (1)
- Biochemie (1)
- Biokompatibilität (1)
- Burkholderia (1)
- CANDLE (1)
- CD13 (1)
- CHO-Zelle (1)
- COVID-19 (1)
- Chagas’ disease (1)
- Collapsin Response Mediator Protein 2 (1)
- Congestion (1)
- DNA (1)
- Docosahexaensäure (1)
- Doublecortin (1)
- Doxorubicin (1)
- Dronedaron (1)
- Dronedarone (1)
- Entwicklungsstörung (1)
- Entzündung (1)
- Epidermal growth factor receptor (1)
- FRET (1)
- Fluoreszenz-Resonanz-Energie-Transfer (1)
- Fructoselysin (1)
- G-quadruplexes (1)
- GADA (1)
- Gas5 (1)
- Gefitinib (1)
- Gen (1)
- Glucose (1)
- Glutaredoxin (1)
- Glutaredoxin 2 (1)
- Glutaredoxine (1)
- Glutathion (1)
- Glutathione (1)
- Glykation (1)
- Grx2 (1)
- HL-1 (1)
- HL-1 Cardiomyocytes (1)
- HL-1 cardiomyocytes (1)
- HLA-DQB1 (1)
- Hepatozyt (1)
- Herpes (1)
- Herpesvirus suis (1)
- Herzrhythmusstörung (1)
- Heterologe Genexpression (1)
- Hormonresistentes Prostatakarzinom (1)
- Hypernephrom (1)
- IA-2A (1)
- IAA (1)
- IDO (1)
- Immuncytochemie (1)
- Immunhistochemie (1)
- Immunosuppression (1)
- Immunreaktion (1)
- Implantat (1)
- Implantation (1)
- In vivo (1)
- Inferior vena cava (1)
- Inflammation (1)
- Influenza A virus (1)
- Inhibitoren (1)
- Insulinsekretion (1)
- Intelligenzminderung (1)
- Interferon <gamma-> (1)
- Interleukin-37 (1)
- Irbesartan (1)
- Islets of Langerhans (1)
- KYNA (1)
- Kinesine (1)
- Klassische Schweinepest Virus (1)
- LA-, HA-MRSA (1)
- Leptin (1)
- Lipopolysaccharid (1)
- M1 macrophage (1)
- M2 macrophage (1)
- MAP-Kinase (1)
- MARK2 (1)
- MSSA (1)
- Makrophage (1)
- Marker Impfstoffe (1)
- Mas Rezeptor (1)
- Metabolic Syndrom (1)
- Metabolisches Syndrom (1)
- MiD51 (1)
- Micro Array (1)
- Mikroglia (1)
- Mitochondrium (1)
- Molekularbiologie (1)
- Molekulare Virologie (1)
- Monozyt (1)
- Mutation (1)
- Myocardial infarction (1)
- Myokardinfarkt (1)
- NADPH oxidase (1)
- NADPH-Oxidase (1)
- NF-κB signal transduction pathway (1)
- NT‐proBNP (1)
- Netrin-Signaling (1)
- Neurobiologie (1)
- Neuroendokrine Differenzierung (1)
- Neurogenese (1)
- Neurologie (1)
- Nicotinamid N-Methyltransferase (1)
- Niedertemperaturplasma (1)
- Nrf2-sinaling (1)
- Nukleophosmin (1)
- Osteosarkom (1)
- Oxidative burst (1)
- Oxidoreduktase (1)
- PC-1 (1)
- PDX-1 (1)
- PRAAS (1)
- PSMA5 (1)
- PSMB10 (1)
- PSMB8 (1)
- Pancreatic Beta-Cell (1)
- Pathoproteomics (1)
- Pax6 (1)
- Pax6(5a) (1)
- Pentetrazol (1)
- Peroxiredoxin (1)
- Phagocytosis (1)
- Phospholipide (1)
- Phosphoproteom (1)
- Phosphoproteomics (1)
- Phosphorylierung (1)
- Pichia pastoris (1)
- Plasmapolymerisation (1)
- Pneumococcal pneumonia (1)
- Posttranslationale Modifikation (1)
- Promotoranalyse (1)
- Prostatakarzinom (1)
- Prote (1)
- Proteasom (1)
- Proteasom-Assoziierte Störungen (1)
- Protein-Protein-Interaktion (1)
- Proteinbiochemie (1)
- Proteom (1)
- Quantifizierung (1)
- RAAS (1)
- ROS (1)
- Rapid Atrial Pacing (1)
- Reactive oxygen species (1)
- Real time quantitative PCR (1)
- Redoxregulation (1)
- Renin-Angiotensin System (1)
- Rezeptor (1)
- SBK2 (1)
- SDS-SP3 protocol (1)
- SILAC (1)
- Schilddrüsenhormon (1)
- Schlaganfall (1)
- Screening (1)
- Signaltransduktion (1)
- Signalwege (1)
- Sonic Hedgehog signaling (1)
- Sra1/Cyfip1 (1)
- Stickstoffmonoxid-Synthase (1)
- Subventrikularzone (1)
- Syndrom (1)
- TGF (1)
- TLR4 signaling (1)
- TRPC (1)
- Tau (1)
- Tegumentproteine (1)
- Tenascin-R (1)
- Thiole (1)
- Thyroid function (1)
- Thyroid-stimulating hormone (1)
- Tiermodell (1)
- Transkriptionsfaktorbindungsstelle (1)
- Tumorbiologie (1)
- Tumormarker (1)
- Typ-1-Diabetes (1)
- Type 1 Diabetes (1)
- Ultrasound (1)
- Verhaltenstest (1)
- Visceral adipose tissue (1)
- Visceral body fat (1)
- Vitamin B6 deficiency (1)
- Wirt-Pathogen-Interaktion (1)
- Wnt (1)
- Wnt-signaling (1)
- Zelllinie (1)
- Zellmigration (1)
- Zellproliferation (1)
- Zusammensetzung (1)
- Zytoskelett (1)
- [Fe-S] Cluster (1)
- acute kidney injury (1)
- airway inflammation (1)
- angiotensin (1)
- angiotensin 1-7 (1)
- antioxidant signaling pathways (1)
- antioxidative Enzyme (1)
- asthma (1)
- atrial (1)
- atrial tissue (1)
- autoimmune (1)
- biofilm (1)
- calorimetry (1)
- cancer (1)
- cancer stem cell (1)
- cardiolipin composition (1)
- castration resistant prostate cancer (1)
- catalytic activity (1)
- codon (1)
- collapsin response mediator protein 2 (1)
- cyclooxygenase (1)
- cystic fibrosis (1)
- cytotoxicity (1)
- de novo mutations (1)
- dihydropyrimidinase-related protein 2 (1)
- drug resistance (1)
- eicosanoids (1)
- endoplasmic reticulum lipid raft-associated protein 2 (1)
- enzyme (1)
- extravasation (1)
- formalin fixed and embedded brain sample (1)
- geistige Behinderung (1)
- gene library (1)
- glutamat-cystein-ligase (1)
- glutaredoxin 2 (1)
- glutaredoxins (1)
- glutathione (1)
- hemolysis (1)
- idiopathic dilated cardiomyopathy (1)
- immunity (1)
- infection (1)
- inflammation (1)
- integrated stress response (1)
- intellectual disability (1)
- interferon (1)
- interferonopathy (1)
- intracellular signalling (1)
- invasion (1)
- katalytische Aktivität (1)
- kinetics (1)
- klarzelliges Nierenzellkarzinom (1)
- kynurenine pathway (1)
- lipid mediator (1)
- mRNA expression (1)
- macrophage (1)
- mass spectrometry (1)
- miRNA (1)
- miRNA 3687 (1)
- miRNA 4417 (1)
- miRNA-1 (1)
- miRNA-328 (1)
- miRNS (1)
- microvascular flow (1)
- mitochondrial dynamics (1)
- mitochondrial fission (1)
- mitochondrial respiration (1)
- mitophagy (1)
- mutations (1)
- neurodegeneration (1)
- neurodevelopmental disorders (1)
- neuroendocrine differentiation (1)
- neutrophil (1)
- nucleophosmin (1)
- oxidative dysbalance (1)
- oxidative stress (1)
- oxidoreductase (1)
- pacing (1)
- pancreatic beta cells (1)
- peroxiredoxin (1)
- phosphoproteomics (1)
- pig (1)
- posttranslational modification (1)
- prostate cancer (1)
- proteasome associated autoinflammatory syndrome (1)
- proteasome-associated autoinflammatory syndrome (1)
- proteasomes (1)
- protein biochemistry (1)
- protein engineering (1)
- protein expression (1)
- protein preparation (1)
- protein-protein interaction (1)
- proteostasis (1)
- quantitative Proteomics (1)
- randomization (1)
- rapid pacing (1)
- rapid-pacing (1)
- reactive oxygen species (1)
- reactive oxygen species (ROS) (1)
- redox (1)
- redox metabolism (1)
- redox relay (1)
- remodeling (1)
- signalling pathways (1)
- snoRNAs (1)
- syndromic (1)
- topology (1)
- trinucleotide building block (1)
- tryptophan (1)
- tumorassoziierte Enzymalteration (1)
- type I interferon (1)
- ubiquitin (1)
- ubiquitin–proteasome system (1)
- unfolded protein response (1)
- virulence (1)
- von Hippel-Lindau-Syndrom (1)
- xGelsolin (1)
- β-Zelle (1)
Institute
- Institut für Med. Biochemie u. Molekularbiologie (65) (remove)
Publisher
- Frontiers Media S.A. (9)
- MDPI (9)
- S. Karger AG (2)
- Springer Nature (2)
- Wiley (2)
- American Society for Microbiology (ASM) (1)
- Elsevier (1)
- Public Library of Science (PLoS) (1)
- SAGE Publications (1)
The Immunomodulator 1-Methyltryptophan Drives Tryptophan Catabolism Toward the Kynurenic Acid Branch
(2020)
Background: Animal model studies revealed that the application of 1-methyltryptophan (1-MT), a tryptophan (TRP) analog, surprisingly increased plasma levels of the TRP metabolite, kynurenic acid (KYNA). Under inflammatory conditions, KYNA has been shown to mediate various immunomodulatory effects. Therefore, the present study aims to confirm and clarify the effects of 1-MT on TRP metabolism in mice as well as in humans.
Methods: Splenocytes from Balb/C or indoleamine 2,3-dioxygenase knockout (IDO1−/−) mice or whole human blood were stimulated with 1-MT for 6, 24, or 36 h. C57BL/6 mice received 1-MT in drinking water for 5 days. Cell-free supernatants and plasma were analyzed for TRP and its metabolites by tandem mass spectrometry (MS/MS).
Results: 1-MT treatment induced an increase in TRP and its metabolite, KYNA in Balb/C, IDO−/− mice, and in human blood. Concurrently, the intermediate metabolite kynurenine (KYN), as well as the KYN/TRP ratio, were reduced after 1-MT treatment. The effects of 1-MT on TRP metabolites were similar after the in vivo application of 1-MT to C57BL/6 mice.
Conclusions: The data indicate that 1-MT induced an increase of KYNA ex vivo and in vivo confirming previously described results. Furthermore, the results of IDO−/− mice indicate that this effect seems not to be mediated by IDO1. Due to the proven immunomodulatory properties of KYNA, a shift toward this branch of the kynurenine pathway (KP) may be one potential mode of action by 1-MT and should be considered for further applications.
Background: Mitochondrial dynamics are important for glucose-stimulated insulin secretion in pancreatic beta cells. The mitochondrial elongation factor MiD51 has been proposed to act as an anchor that recruits Drp1 from the cytosol to the outer mitochondrial membrane. Whether MiD51 promotes mitochondrial fusion by inactivation of Drp1 is a controversial issue. Since both the underlying mechanism and the effects on mitochondrial function remain unknown, this study was conducted to investigate the role of MiD51 in beta cells.
Methods: Overexpression and downregulation of MiD51 in mouse insulinoma 6 (MIN6) and mouse islet cells was achieved using the pcDNA expression vector and specific siRNA, respectively. Expression of genes regulating mitochondrial dynamics and autophagy was analyzed by quantitative Real-Time PCR, glucose-stimulated insulin secretion by ELISA, and cellular oxygen consumption rate by optode sensor technology. Mitochondrial membrane potential and morphology were visualized after TMRE and MitoTracker Green staining, respectively. Immunofluorescence analyses were examined by confocal microscopy.
Results: MiD51 is expressed in insulin-positive mouse and human pancreatic islet and MIN6 cells. Overexpression of MiD51 resulted in mitochondrial fragmentation and cluster formation in MIN6 cells. Mitochondrial membrane potential, glucose-induced oxygen consumption rate and glucose-stimulated insulin secretion were reduced in MIN6 cells with high MiD51 expression. LC3 expression remained unchanged. Downregulation of MiD51 resulted in inhomogeneity of the mitochondrial network in MIN6 cells with hyperelongated and fragmented mitochondria. Mitochondrial membrane potential, maximal and glucose-induced oxygen consumption rate and insulin secretion were diminished in MIN6 cells with low MiD51 expression. Furthermore, reduced Mfn2 and Parkin expression was observed. Based on MiD51 overexpression and downregulation, changes in the mitochondrial network structure similar to those in MIN6 cells were also observed in mouse islet cells.
Conclusion: We have demonstrated that MiD51 plays a pivotal role in regulating mitochondrial function and hence insulin secretion in MIN6 cells. We propose that this anchor protein of Drp1 is important to maintain a homogeneous mitochondrial network and to avoid morphologies such as hyperelongation and clustering which are inaccessible for degradation by autophagy. Assuming that insulin granule degradation frequently suppresses autophagy in beta cells, MiD51 could be a key element maintaining mitochondrial health.
Endogenous redox systems not only counteract oxidative damage induced by high levels of hydroxyl radicals (OH·) under pathological conditions, but also shape redox signaling as a key player in the regulation of physiological processes. Second messengers like hydrogen peroxide and nitric oxide, as well as redox enzymes of the Thioredoxin (Trx) family, including Trxs, glutaredoxins (Grxs), and peroxiredoxins (Prxs) modulate reversible, oxidative modifications of proteins. Thereby redox regulation is part of various cellular processes such as the immune response and Trx proteins have been linked in different disorders including inflammatory diseases. Here, we have analyzed the protein distribution of representative oxidoreductases of the Trx fold protein family—Trx1, Grx1, Grx2, and Prx2—in a murine model of allergic asthma bronchiale, as well as their potential therapeutic impact on type-2 driven airway inflammation. Ovalbumin (OVA) sensitization and challenge using the type-2 prone Balb/c mouse strain resulted in increased levels of all investigated proteins in distinct cellular patterns. While concomitant treatment with Grx1 and Prx2 did not show any therapeutic impact on the outcome of the disease, Grx2 or Trx1 treatment before and during the OVA challenge phase displayed pronounced protective effects on the manifestation of allergic airway inflammation. Eosinophil numbers and the type-2 cytokine IL-5 were significantly reduced while lung function parameters profoundly improved. The number of macrophages in the bronchoalveolar lavage (BAL) did not change significantly, however, the release of nitric oxide that was linked to airway inflammation was successfully prevented by enzymatically active Grx2 ex vivo. The Grx2 Cys-X-X-Ser mutant that facilitates de-/glutathionylation, but does not catalyze dithiol/disulfide exchange lost the ability to protect from airway hyper reactivity and to decrease NO release by macrophages, however, it reduced the number of infiltrating immune cells and IL-5 release. Altogether, this study demonstrates that specific redox proteins and particular enzyme activities protect against inflammatory damage. During OVA-induced allergic airway inflammation, administration of Grx2 exerts beneficial and thus potentially therapeutic effects.
Despite their very close structural similarity, CxxC/S-type (class I) glutaredoxins (Grxs) actas oxidoreductases, while CGFS-type (class II) Grxs act as FeS cluster transferases. Here weshow that the key determinant of Grx function is a distinct loop structure adjacent to theactive site. Engineering of a CxxC/S-type Grx with a CGFS-type loop switched its functionfrom oxidoreductase to FeS transferase. Engineering of a CGFS-type Grx with a CxxC/S-typeloop abolished FeS transferase activity and activated the oxidative half reaction of the oxi-doreductase. The reductive half-reaction, requiring the interaction with a second GSHmolecule, was enabled by switching additional residues in the active site. We explain howsubtle structural differences, mostly depending on the structure of one particular loop, act inconcert to determine Grx function.
The failure of insulin-producingβ-cells is the underlying cause of hyperglycemia in diabetes mellitus.β-cell decay has been linked to hypoxia, chronic inflammation,and oxidative stress. Thioredoxin (Trx) proteins are major actors in redox signaling and essential for signal transduction and the cellular stress response. We haveanalyzed the cytosolic, mitochondrial, and extracellular Trx system proteins in hypoxic and cytokine-induced stress usingβ-cell culture, isolated pancreatic islets, andpancreatic islet transplantation modelling low oxygen supply.Protein levels of cytosolic Trx1 and Trx reductase (TrxR) 1 significantly decreased, while mitochondrial Trx2 and TrxR2 increased upon hypoxia and reox-ygenation. Interestingly, Trx1 was secreted byβ-cells during hypoxia. Moreover, murine and human pancreatic islet grafts released Trx1 upon glucose stimulation.Survival of transplanted islets was substantially impaired by the TrxR inhibitor auranofin.Since a release was prominent upon hypoxia, putative paracrine effects of Trx1 onβ-cells were examined. In fact, exogenously added recombinant hTrx1 mitigatedapoptosis and preserved glucose sensitivity in pancreatic islets subjected to hypoxia and inflammatory stimuli, dependent on its redox activity. Human subjects werestudied, demonstrating a transient increase in extracellular Trx1 in serum after glucose challenge. This increase correlated with better pancreatic islet function.Moreover, hTrx1 inhibited the migration of primary murine macrophages.In conclusion, our study offers evidence for paracrine functions of extracellular Trx1 that improve the survival and function of pancreaticβ-cells.
Abstract
Aims
Treating patients with acute decompensated heart failure (ADHF) presenting with volume overload is a common task. However, optimal guidance of decongesting therapy and treatment targets are not well defined. The inferior vena cava (IVC) diameter and its collapsibility can be used to estimate right atrial pressure, which is a measure of right‐sided haemodynamic congestion. The CAVA‐ADHF‐DZHK10 trial is designed to test the hypothesis that ultrasound assessment of the IVC in addition to clinical assessment improves decongestion as compared with clinical assessment alone.
Methods and results
CAVA‐ADHF‐DZHK10 is a randomized, controlled, patient‐blinded, multicentre, parallel‐group trial randomly assigning 388 patients with ADHF to either decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment or clinical assessment alone. IVC ultrasound will be performed daily between baseline and hospital discharge in all patients. However, ultrasound results will only be reported to treating physicians in the intervention group. Treatment target is relief of congestion‐related signs and symptoms in both groups with the additional goal to reduce the IVC diameter ≤21 mm and increase IVC collapsibility >50% in the intervention group. The primary endpoint is change in N‐terminal pro‐brain natriuretic peptide from baseline to hospital discharge. Secondary endpoints evaluate feasibility, efficacy of decongestion on other scales, and the impact of the intervention on clinical endpoints.
Conclusions
CAVA‐ADHF‐DZHK10 will investigate whether IVC ultrasound supplementing clinical assessment improves decongestion in patients admitted for ADHF.
Zusammenfassung
Im Rahmen immunologischer Erkrankungen, wie Autoimmun- oder inflammatorischer Erkrankungen, Erkrankungen des zentralen Nervensystems oder Krebserkrankungen spielen Peptidasen eine wichtige Rolle [1, 2]. Die Exopeptidasen Membran-Alanyl-Aminopeptidase N (APN/CD13) und Dipeptidylpeptidase IV (DP IV/CD26) sind essentiell für die Regulation vieler biologischer Prozesse, insbesondere für die Autoimmunität und die Inflammation [3-5]. Literaturdaten und Vorarbeiten verschiedener Arbeitsgruppen belegen immunmodulatorische Eigenschaften von Inhibitoren der enzymatischen Aktivität der APN. Sowohl in vitro als auch in verschiedenen Krankheitsmodellen der Maus in vivo, zeigten sich therapeutisch relevante immunsuppressive Effekte dieser Inhibitoren [7, 11]. Mechanistisch liegen diesen positiven Wirkungen unter anderem eine Hemmung der Produktion und Sekretion proinflammatorischer Zytokine, sowie die Verstärkung der Produktion und Sekretion immunsuppressiver Zytokine zu Grunde [5]. Die Inhibitoren scheinen auch einen immunmodulatorischen Einfluss auf den Wnt Signalweg zu haben, der als Signaltransduktionsweg wichtige Aufgaben in der Regulation von Zellmigration, Polarität, interzellulärer Kontakte und für die frühe Embryonalentwicklung übernimmt [47]. Im Rahmen dieser Arbeit wurde sowohl der Einfluss verschiedener Inhibitoren der APN als auch des genetischen CD13-Knockouts in Mäusen auf die Aktivierung verschiedener Mikrogliazellpopulationen und auf die Expression von Komponenten des Wnt Signalweges untersucht. In Abhängigkeit von der Aktivierung war sowohl eine gesteigerte Expression proinflammatorischer Zytokine, als auch eine Hemmung der Komponenten des Wnt Signalweges in BV2 Mikrogliazellen zu beobachten. In BV2 Mikrogliazellen konnten keine signifikanten Einflüsse durch die Inhibitoren A1.002 und IP10.C9 detektiert werden. Lediglich durch den CD13-Antikörper My 7 konnten immunsuppressive Effekte in aktivierten BV2 Mikrgoliazellen beobachtet werden. In CD13-Knockout Mäusen konnte eine signifikante Reduktion der Wnt 10b positiven Mikrogliazellen gezeigt werden. In der Zusammenschau aller Ergebnisse lassen sich regulatorische Zusammenhänge zwischen der Aktivität der Mikrogliazellen, sowie der APN und dem Wnt Signalweg aufzeigen. Daher erscheinen weiterführende Analysen in primären isolierten Mikrogliazellen sinnvoll, um die Bedeutung von Inhibitoren der APN in neuronalen Zellen zu ermitteln. Dabei spielen nicht nur die Inhibitoren selbst, sondern auch deren Inkubationsbedingungen im Verhältnis zur LPS-vermittelten Zellaktivierung eine entscheidende Rolle.
Survival, development, and function of cells depend on numerous signaling pathways or-
chestrating the response to external and internal stimuli. Besides the well-established signaling through reversible phosphorylation, the concept of specific, spatio-temporal redox modifi-
cations of protein cysteinyl and methionyl side chains that regulate the biological function of these proteins is supported by an overwhelming amount of data. Although the specific reduction of protein redox modifications has been studied intensively, the oxidation of protein side chains was thought to be a result of so-called ‘oxidative stress’. However, this term has been increasingly challenged, since signaling pathways depend on specific, spatio-temporal oxidation of target proteins, most likely catalyzed by specific enzymes. The discovery of MICAL (molecule interacting with CasL) proteins evinced
the first examples of specific oxidases in signal transduction in the redox regulation of cellular functions.As part of the semaphorin signaling pathway, MICAL proteins were characterized to stereospecifically oxidize methionyl residues in actin, thereby regulating actin deolymerization, a process important in neurogenesis and cell migration. This oxidation can be reversed by the specific methionine-R-sulfoxide eductase B1. Besides the regulation of actin dynamics, MICALs are involved in the regulation of cell proliferation and
apoptosis, and the production of hydrogen peroxide may qualify them as specific oxidases also for cysteinyl residues.
Das Prostatakarzinom ist die häufigste Krebserkrankung des Mannes und die Inzidenz nimmt seit fast drei Jahrzehnten stetig zu. Moderne Therapieverfahren führen zu einem längeren Überleben der Patienten, durchaus auch mit kompletter Remission. Dennoch können im Rahmen der Therapie, insbesondere unter der Hormonentzugstherapie, weitere Veränderungen des Tumors zu einer Progression der Erkrankung führen. Durch den Verlust der Androgenabhängigkeit des Tumors bezeichnet man dies als kastrationsresistentes Prostatakarzinom. Dieser Progress ist häufig mit einer Zunahme von neuroendokrinen Zellen assoziiert, die im Rahmen einer sog. Neuroendokrinen Transdifferenzierung (NETD) aus den Drüsenzellen des Adenokarzinoms entstehen.
Im Rahmen der vorliegenden Arbeit wurde eine solche Differenzierung durch die Kultivierung der Prostatakarzinomzelllinie LNCaP in Gegenwart von IL-6 simuliert. Diese experimentell erzeugte NETD konnte sowohl durch die Überexpression typischer Markerproteine, als auch durch die charakteristische Veränderung der Zellmorphologie nachgewiesen werden.
Um die molekularbiologischen Mechanismen im Rahmen der NETD besser zu verstehen, wurde das Proteom der differenzierten Zellen mit dem von Kontrollzellen verglichen. Differentiell exprimierte Proteine wurden mittels Massenspektrometrie identifiziert.
Die Proteine Gelsolin, Septin 7 und PC1 wurden in weiterführenden Experimenten validiert. Im Kontext der NETD erwies sich Gelsolin aufgrund seiner bekannten Funktionen als besonders interessant. Daher wurde dessen Expression mittels RNA- Interferenz moduliert und die Auswirkungen auf Zellfunktion und Morphologie untersucht. Gelsolin ist ein multifunktionelles Protein, welches sowohl Zytoskelett- modulierend wirkt, als auch in die Regulation der Apoptose involviert ist. Die vorliegende Arbeit zeigt, dass ein Gelsolin knockdown eine deutliche Expressionserhöhung der aktivierten Caspase 3 bewirkt, was mit einer erhöhten Apoptoserate korreliert. Naheliegend war es auch der Frage nachzugehen, ob Gelsolin an der Ausprägung der charakteristischen morphologischen Veränderungen im Zuge der NETD beteiligt ist. Der begleitend zur IL-6-Behandlung durchgeführte knockdown ergab jedoch keinen relevanten Einfluss auf die Ausbildung von Zellausläufern.
Eine auf immunzytochemischer Färbetechnik basierende Analyse zeigte eine Kolokalisation von Gelsolin mit den Proteinen VDAC1 und PC1. Beide sind als Stabilisatoren des mitochondrialen Membranpotenzials bekannt. Somit könnte Gelsolin als Adapterprotein im Rahmen der Apoptoseregulation fungieren.
Die vorliegende Arbeit hat differentiell exprimierte Proteine identifiziert, die im Kontext einer NETD erstmals beschrieben wurden und somit den Weg bereitet, den Erkenntnisgewinn zu molekularbiologischen Abläufen bei der Entwicklung eines kastrationsresistenten Prostatakarzinoms auszuweiten.